Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Kiniksa Pharmaceuticals International, plc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +13 vs. Q2 2022
- Shares held
- 29.9M
- +2.05K (0.0%) vs. Q2 2022
- Total value
- $383.2M
- +$92.8M (+31.9%) vs. Q2 2022
- New holders
- 22
- 38 more added
- Sold out
- 9
- 27 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KNSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 267 | $2.99B |
| Q1 2026 | 228 | $2.18B |
| Q4 2025 | 224 | $1.77B |
| Q3 2025 | 204 | $1.59B |
| Q2 2025 | 189 | $1.10B |
| Q1 2025 | 176 | $889.4M |
| Q4 2024 | 160 | $773.1M |
| Q3 2024 | 176 | $991.2M |
| Q2 2024 | 133 | $659.4M |
| Q1 2024 | 154 | $768.1M |
| Q4 2023 | 142 | $600.4M |
| Q3 2023 | 134 | $605.8M |
| Q2 2023 | 127 | $447.7M |
| Q1 2023 | 132 | $339.6M |
| Q4 2022 | 125 | $450.0M |
| Q3 2022 | 104 | $383.2M |
| Q2 2022 | 92 | $290.5M |
| Q1 2022 | 96 | $306.0M |
| Q4 2021 | 103 | $346.4M |
| Q3 2021 | 101 | $332.0M |
| Q2 2021 | 102 | $402.0M |
| Q1 2021 | 105 | $537.6M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Kiniksa Pharmaceuticals International, plc; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 2,920,023 | $37.5M | 0.99% | 00.0% | Unchanged |
| Pictet Asset Management SA | 3,037,861 | $39.0M | 0.06% | −493,941−14.0% | Reduced |
| Vanguard Group Inc | 3,079,192 | $39.5M | 0.00% | +151,211+5.2% | Added |
| BlackRock Inc. | 3,628,460 | $46.6M | 0.00% | +93,103+2.6% | Added |
| Great Point Partners LLC | 0 | $0 | 0.00% | −1,204,028−100.0% | Sold out |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −814,250−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −332,893−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −234,830−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −14,482−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −10,546−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1,276−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −1,184−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Exane Derivatives | – | – | – | – | Not filed |